NEW YORK (GenomeWeb) – Serametrix, a San Diego-based company specializing in immune monitoring assays, has received CLIA certification for its laboratory in Carlsbad, California, the firm said recently.
The certification enables the company to offer its myeloid-derived suppressor cell assay for cancer patients. The flow cytometry-based assay was developed at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center and was licensed by Serametrix in 2013.